Back to News
Market Impact: 0.32
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
Source: businesswire.com
Legal & LitigationHealthcare & Biotech
Capricor Therapeutics faces a pending securities-fraud class action after its stock fell 64%. BFA Law notified investors of a September 28 deadline to contact the firm, creating material legal and reputational risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.72
Ticker Sentiment
CAPR-0.95
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- United Therapeutics’ Rothblatt sells $4.7 million in stock
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday